ethyl (Z)-3-(methylamino)-2-butenoate | 21759-70-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl (Z)-3-(methylamino)-2-butenoate
• 英文别名: (Z)-ethyl 3-(methylamino)but-2-enoate；ethyl (Z)-3-(methylamino)but-2-enoate；3-methylamino-2-butenoate d'ethyle；3-(Methylamino)crotonsaeure-ethylester；ethyl-3-aminomethyl crotonate；Ethyl 3-methylaminocrotonate
• CAS: 21759-70-6
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: FARYTWBWLZAXNK-WAYWQWQTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl (Z)-3-(methylamino)-2-butenoate 在 sodium 、 异丙醇 作用下， 以 四氢呋喃 为溶剂， 以66%的产率得到3-甲基氨基-1-丁醇
  参考文献：
  名称：

  Chemo- and Diastereoselective Reduction of .beta.-Enamino Esters: A Convenient Synthesis of Both cis- and trans-.gamma.-Amino Alcohols and .beta.-Amino Esters

  摘要：

  Convenient procedures for the chemo- and diastereoselective reduction of beta-enamino esters 1 are described. Both cis- and trans-gamma-amino alcohols 2 or beta-amino esters 3 can be prepared by reduction of beta-enamino esters 1, readily available starting materials, with the use of inexpensive reagents Nali-PrOH or NaHbB(OAc)(3)/AcOH, respectively, and the appropriate reduction conditions. The mechanisms and diastereoselectivities for the reductions are discussed. The relative configurations and conformations of the diastereoisomeric gamma-amino alcohols 2 and beta-amino esters 3 obtained are established by H-1 and C-13 NMR study and unequivocally set by their cyclic derivatives tetrahydro-1,3-oxazines 4.

  DOI：

  10.1021/jo00097a039
• 作为产物：
  描述：

  乙酰乙酸乙酯 在 甲胺 作用下， 以 水 为溶剂， 以70%的产率得到ethyl (Z)-3-(methylamino)-2-butenoate
  参考文献：
  名称：

  Certain 2-phenyl-4-oxo-nicotinates and their use for inducing male

  摘要：

  本发明涉及公式如下的化合物：##STR1## 其中，R.sub.1是可选择取代的烷基或烯基基团；R.sub.2、R.sub.5和R.sub.6中至少有一个是##STR2## 其中，（1）当R.sub.2是##STR3##时，R.sub.5是氢原子、烷基或卤素原子，R.sub.6是氢原子或烷基；（2）当R.sub.5是##STR4##时，R.sub.2是烷基，R.sub.6是氢原子或烷基；（3）当R.sub.6是##STR5##时，R.sub.2是可选择取代的（C.sub.1-C.sub.6）烷基或（C.sub.3-C.sub.6）烯基基团，R.sub.5是氢原子、（C.sub.1-C.sub.6）烷基或卤素原子；（4）当R.sub.2和R.sub.6都独立地为##STR6##时，R.sub.5是氢原子或烷基；Y是氢原子或烷基；X是氢原子、卤素原子、三卤甲基基团等；n是1到3的整数；或其农学上可接受的碱金属或酸加成盐。这些化合物对单子叶作物具有化学杂交剂的作用，特别是对小麦、玉米、大麦、稻米、黑麦、小黑麦和饲料作物具有很好的效果。

  公开号：

  US04714492A1

文献信息

• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：INTERMUNE, INC.

  公开号：US20140200215A1

  公开（公告）日：2014-07-17

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供的是化合物、制造这些化合物的方法、包含这些化合物的药物组合物和药品，以及使用这些化合物来治疗、预防或诊断与一个或多个溶血磷脂酸受体相关的疾病、失调或状况的方法。
• [EN] SERINE/THREONINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE SÉRINE/THRÉONINE KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2015103137A1

  公开（公告）日：2015-07-09

  Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.

  提供具有公式I的化合物或其立体异构体、互变异构体或药用可接受盐，这些化合物用于治疗疾病。公开了使用公式I的化合物或其立体异构体、互变异构体或药用可接受盐，用于体外、原位和体内诊断、预防或治疗此类疾病或相关病理状况的方法。
• Lewis Acid-Catalyzed Generation of CC and CN Bonds on π-Deficient Heterocyclic Substrates
  作者：Matteo Staderini、Maria Laura Bolognesi、J. Carlos Menéndez

  DOI：10.1002/adsc.201400674

  日期：2015.1.12

  to the efficient and completely regioselective generation of aromatic CC and CN bonds. The method is simple, rapid, general and inexpensive, and can be performed without the use of dried solvents. Most of the synthetized compounds are new and in many cases the work‐up required only filtration. Furthermore, this is the first example of the use of a Lewis acid as a catalyst for heteroarylation, vinylation

  在催化量的三氯化铟的存在下，对一系列卤化的氮杂环和不同种类的亲核试剂进行聚焦微波辐照可有效且完全区域选择性地生成芳族CC和CN键。该方法简单，快速，通用且廉价，并且可以在不使用干燥溶剂的情况下进行。大多数合成的化合物都是新化合物，在许多情况下，仅需过滤即可进行后处理。此外，这是使用路易斯酸作为催化剂在π缺陷杂环底物上进行杂芳基化，乙烯基化和胺化反应的第一个例子。
• Process for producing 2-amino-alkenylsulfonylurea derivatives
  申请人：Hoechst Aktiengesellschaft

  公开号：US04725679A1

  公开（公告）日：1988-02-16

  The novel 2-amino-alkenylsulfonylureas of the formula (I) ##STR1## in which R.sub.1 and R.sub.2 denote hydrogen, alkyl, cycloalkyl or (substituted) phenyl, or R.sub.1 and R.sub.2, together with the common nitrogen atom, form a 5-membered to 7-membered (hetero)aliphatic ring, R.sub.3 denotes hydrogen, cycloalkyl, alkyl, alk(en)(yn)yloxy, alkylsulfen(in)(on)yl, --SO.sub.2 (N)(mono- or di-alkyl), (substituted) phenyl, benzyl, substituted hydroxycarbonyl or (substituted) aminocarbonyl, R.sub.4 has the meaning of R.sub.3 and additionally denote formyl, alkanoyl, (substituted) benzoyl, cycloalkylcarbonyl or C.sub.6 H.sub.5 --CH.sub.2 --O--CO--, or R.sub.3 and R.sub.4, together with the olefinic carbon atoms connecting them, form a 5-membered to 8-membered aliphatic ring system, R.sub.5 denotes H, alkyl, alkenyl, alkynyl, alkoxy or alkoxycarbonyl and R.sub.6 denotes alkyl or cycloalkyl, (substituted) phenyl or a (substituted) pyrimidinyl or (substituted) triazinyl ring, are useful intermediates for the preparation of plant protection agents.

  化合物2-氨基烯烃磺酰脲的化学式（I）##STR1##中，R.sub.1和R.sub.2表示氢、烷基、环烷基或（取代）苯基，或者R.sub.1和R.sub.2与共同的氮原子一起形成一个5-至7-成员的（杂）脂肪环，R.sub.3表示氢、环烷基、烷基、烷烯基氧、烷基砜（亚）氧基、-SO.sub.2（N）（单烷基或二烷基）、（取代）苯基、苄基、取代羟基羰基或（取代）氨基羰基，R.sub.4具有R.sub.3的含义，并额外表示甲酰基、烷酰基、（取代）苯甲酰基、环烷基羰基或C.sub.6 H.sub.5-CH.sub.2-O-CO-，或者R.sub.3和R.sub.4与连接它们的烯烃碳原子一起形成一个5-至8-成员的脂肪环系统，R.sub.5表示H、烷基、烯烃基、炔基、烷氧基或烷氧羰基，R.sub.6表示烷基或环烷基、（取代）苯基或（取代）嘧啶基或（取代）三嗪基环，这些化合物是制备植物保护剂的有用中间体。
• SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE
  申请人：AbbVie Inc.

  公开号：US20170073353A1

  公开（公告）日：2017-03-16

  Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式(I)的化合物及其药用盐，其中R1、R2和R3如规范中定义的那样，可用于治疗通过或通过正向变构调节γ-氨基丁酸B（GABA-B）受体预防或改善的症状或疾病。描述了制备这些化合物的方法。还描述了式(I)的化合物的药物组合物，以及使用这些化合物和组合物的方法。